Drugs.com - Clinical Trials

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

BOSTON--(BUSINESS WIRE)--Dec. 19, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful...

Feb 9, 2025 - 21:44
 0
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
BOSTON--(BUSINESS WIRE)--Dec. 19, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful...
Read More

Tags:

Previous Article

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staph...

Next Article

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the ...

Related Posts

Lundbeck’s Potential Treatment Amlenetug for Multiple System Atrophy Receives Fast Track Designation From the FDA

Lundbeck’s Potential Treatment Amlenetug for Multiple S...

Feb 17, 2025  0

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Novo Nordisk Successfully Completes Phase 1b/2a Trial w...

Feb 9, 2025  0

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

Johnson & Johnson’s Posdinemab and Tau Active Immunothe...

Feb 9, 2025  0